电原包和免疫抑制剂成功治疗获得性无核细胞血小板减少症。

IF 2.5 3区医学 Q3 CELL BIOLOGY

Platelets Pub Date : 2022-08-18 Epub Date: 2021-12-16 DOI:10.1080/09537104.2021.2012140

Hong Tian, Danqing Kong, Yun Li, Chengyuan Gu, Ziqiang Yu, Zhaoyue Wang, Depei Wu, Jie Yin

{"title":"电原包和免疫抑制剂成功治疗获得性无核细胞血小板减少症。","authors":"Hong Tian, Danqing Kong, Yun Li, Chengyuan Gu, Ziqiang Yu, Zhaoyue Wang, Depei Wu, Jie Yin","doi":"10.1080/09537104.2021.2012140","DOIUrl":null,"url":null,"abstract":"Acquired amegakaryocytic thrombocypenia (AAMT) is an extremely rare hematologic disorder and standard treatment strategy has not been established. We described herein two cases of AAMT who were fully responded to eltrombopag and immunosuppressant. Patient 1 was refractory to steroid, IVIG and recombinant human thrombopoietin (rhTPO). Patient 2 did not respond to high dosage of steroid, IVIG, rhTPO and rituximab. Moreover, his AAMT progressed to aplastic anemia in 5 months. Both patients took eltrombopag and immunosuppressant, then they achieved long-term remission without obvious side effects. Our findings suggest that this combination can be a valuable alternative in AAMT.","PeriodicalId":20268,"journal":{"name":"Platelets","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant.\",\"authors\":\"Hong Tian, Danqing Kong, Yun Li, Chengyuan Gu, Ziqiang Yu, Zhaoyue Wang, Depei Wu, Jie Yin\",\"doi\":\"10.1080/09537104.2021.2012140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Acquired amegakaryocytic thrombocypenia (AAMT) is an extremely rare hematologic disorder and standard treatment strategy has not been established. We described herein two cases of AAMT who were fully responded to eltrombopag and immunosuppressant. Patient 1 was refractory to steroid, IVIG and recombinant human thrombopoietin (rhTPO). Patient 2 did not respond to high dosage of steroid, IVIG, rhTPO and rituximab. Moreover, his AAMT progressed to aplastic anemia in 5 months. Both patients took eltrombopag and immunosuppressant, then they achieved long-term remission without obvious side effects. Our findings suggest that this combination can be a valuable alternative in AAMT.\",\"PeriodicalId\":20268,\"journal\":{\"name\":\"Platelets\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2022-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Platelets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09537104.2021.2012140\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/12/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Platelets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09537104.2021.2012140","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 2

摘要

获得性无核细胞血小板减少症(AAMT)是一种极其罕见的血液疾病，标准的治疗策略尚未建立。我们在此描述了两例AAMT患者，他们对电曲巴格和免疫抑制剂完全有反应。患者1对类固醇、IVIG和重组人血小板生成素(rhTPO)耐药。患者2对大剂量类固醇、IVIG、rhTPO和利妥昔单抗无反应。此外，他的AAMT在5个月内发展为再生障碍性贫血。两例患者均采用依曲巴格联合免疫抑制剂治疗，均获得长期缓解，无明显副作用。我们的研究结果表明，这种组合可能是AAMT的一种有价值的替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant.

Acquired amegakaryocytic thrombocypenia (AAMT) is an extremely rare hematologic disorder and standard treatment strategy has not been established. We described herein two cases of AAMT who were fully responded to eltrombopag and immunosuppressant. Patient 1 was refractory to steroid, IVIG and recombinant human thrombopoietin (rhTPO). Patient 2 did not respond to high dosage of steroid, IVIG, rhTPO and rituximab. Moreover, his AAMT progressed to aplastic anemia in 5 months. Both patients took eltrombopag and immunosuppressant, then they achieved long-term remission without obvious side effects. Our findings suggest that this combination can be a valuable alternative in AAMT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Platelets 医学-细胞生物学

CiteScore

6.70

自引率

3.00%

发文量

审稿时长

1 months

期刊介绍： Platelets is an international, peer-reviewed journal covering all aspects of platelet- and megakaryocyte-related research. Platelets provides the opportunity for contributors and readers across scientific disciplines to engage with new information about blood platelets. The journal’s Methods section aims to improve standardization between laboratories and to help researchers replicate difficult methods. Research areas include: Platelet function Biochemistry Signal transduction Pharmacology and therapeutics Interaction with other cells in the blood vessel wall The contribution of platelets and platelet-derived products to health and disease The journal publishes original articles, fast-track articles, review articles, systematic reviews, methods papers, short communications, case reports, opinion articles, commentaries, gene of the issue, and letters to the editor. Platelets operates a single-blind peer review policy. Authors can choose to publish gold open access in this journal.